Intermittent fasting for the prevention of cardiovascular disease

Mohammed Allaf, Hussein Elghazaly, Omer G Mohamed, Mohamed Firas Khan Fareen, Sadia Zaman, Abdul-Majeed Salmasi, Kostas Tsilidis, Abbas Dehghan, Mohammed Allaf, Hussein Elghazaly, Omer G Mohamed, Mohamed Firas Khan Fareen, Sadia Zaman, Abdul-Majeed Salmasi, Kostas Tsilidis, Abbas Dehghan

Abstract

Background: Cardiovascular disease (CVD) is the leading cause of death worldwide. Lifestyle changes are at the forefront of preventing the disease. This includes advice such as increasing physical activity and having a healthy balanced diet to reduce risk factors. Intermittent fasting (IF) is a popular dietary plan involving restricting caloric intake to certain days in the week such as alternate day fasting and periodic fasting, and restricting intake to a number of hours in a given day, otherwise known as time-restricted feeding. IF is being researched for its benefits and many randomised controlled trials have looked at its benefits in preventing CVD.

Objectives: To determine the role of IF in preventing and reducing the risk of CVD in people with or without prior documented CVD.

Search methods: We conducted our search on 12 December 2019; we searched CENTRAL, MEDLINE and Embase. We also searched three trials registers and searched the reference lists of included papers. Systematic reviews were also viewed for additional studies. There was no language restriction applied.

Selection criteria: We included randomised controlled trials comparing IF to ad libitum feeding (eating at any time with no specific caloric restriction) or continuous energy restriction (CER). Participants had to be over the age of 18 and included those with and without cardiometabolic risk factors. Intermittent fasting was categorised into alternate-day fasting, modified alternate-day fasting, periodic fasting and time-restricted feeding.

Data collection and analysis: Five review authors independently selected studies for inclusion and extraction. Primary outcomes included all-cause mortality, cardiovascular mortality, stroke, myocardial infarction, and heart failure. Secondary outcomes include the absolute change in body weight, and glucose. Furthermore, side effects such as headaches and changes to the quality of life were also noted. For continuous data, pooled mean differences (MD) (with 95% confidence intervals (CIs)) were calculated. We contacted trial authors to obtain missing data. We used GRADE to assess the certainty of the evidence. MAIN RESULTS: Our search yielded 39,165 records after the removal of duplicates. From this, 26 studies met our criteria, and 18 were included in the pooled analysis. The 18 studies included 1125 participants and observed outcomes ranging from four weeks to six months. No studies included data on all-cause mortality, cardiovascular mortality, stroke, myocardial infarction, and heart failure at any point during follow-up. Of quantitatively analysed data, seven studies compared IF with ab libitum feeding, eight studies compared IF with CER, and three studies compared IF with both ad libitum feeding and CER. Outcomes were reported at short term (≤ 3 months) and medium term (> 3 months to 12 months) follow-up. Body weight was reduced with IF compared to ad libitum feeding in the short term (MD -2.88 kg, 95% CI -3.96 to -1.80; 224 participants; 7 studies; low-certainty evidence). We are uncertain of the effect of IF when compared to CER in the short term (MD -0.88 kg, 95% CI -1.76 to 0.00; 719 participants; 10 studies; very low-certainty evidence) and there may be no effect in the medium term (MD -0.56 kg, 95% CI -1.68 to 0.56; 279 participants; 4 studies; low-certainty evidence). We are uncertain about the effect of IF on glucose when compared to ad libitum feeding in the short term (MD -0.03 mmol/L, 95% CI -0.26 to 0.19; 95 participants; 3 studies; very-low-certainty of evidence) and when compared to CER in the short term: MD -0.02 mmol/L, 95% CI -0.16 to 0.12; 582 participants; 9 studies; very low-certainty; medium term: MD 0.01, 95% CI -0.10 to 0.11; 279 participants; 4 studies; low-certainty evidence). The changes in body weight and glucose were not deemed to be clinically significant. Four studies reported data on side effects, with some participants complaining of mild headaches. One study reported on the quality of life using the RAND SF-36 score. There was a modest increase in the physical component summary score.

Authors' conclusions: Intermittent fasting was seen to be superior to ad libitum feeding in reducing weight. However, this was not clinically significant. There was no significant clinical difference between IF and CER in improving cardiometabolic risk factors to reduce the risk of CVD. Further research is needed to understand the safety and risk-benefit analysis of IF in specific patient groups (e.g. patients with diabetes or eating disorders) as well as the effect on longer-term outcomes such as all-cause mortality and myocardial infarction.

Trial registration: ClinicalTrials.gov NCT03652532 NCT01769976 NCT02679989 NCT02449148 NCT02673515 NCT02480504 NCT03404271 NCT00960505 NCT01741298 NCT02411838 NCT02169778 NCT02258399 NCT02134860 NCT03372109 NCT01571310 NCT02247076 NCT03528317 NCT01659450 NCT00099151 NCT00183027 NCT01754350 NCT01895179 NCT01964118 NCT02287103 NCT02525419 NCT02633722 NCT02970188 NCT03459703 NCT03569852 NCT03574103 NCT04009239 NCT01059760 NCT00467220 NCT02148458 NCT02606669 NCT02948517 NCT03792282.

Conflict of interest statement

MA, HE, OM, SZ, MF, AD, AS and KS all state that there is no conflict of interest.

Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Figures

1
1
Study flow diagram.
2
2
'Risk of bia's summary: review authors' judgements about each risk of bias item for each included study.
3
3
'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
1.1. Analysis
1.1. Analysis
Comparison 1: IF vs Ad libitum (Short term), Outcome 1: Absolute change in body weight (kg)
1.2. Analysis
1.2. Analysis
Comparison 1: IF vs Ad libitum (Short term), Outcome 2: Absolute change in BMI (kg/m2).
1.3. Analysis
1.3. Analysis
Comparison 1: IF vs Ad libitum (Short term), Outcome 3: Absolute change in waist circumference (cm)
1.4. Analysis
1.4. Analysis
Comparison 1: IF vs Ad libitum (Short term), Outcome 4: Absolute change in total cholesterol levels (TC) (mmol/L)
1.5. Analysis
1.5. Analysis
Comparison 1: IF vs Ad libitum (Short term), Outcome 5: Absolute change in LDL (mmol/L
1.6. Analysis
1.6. Analysis
Comparison 1: IF vs Ad libitum (Short term), Outcome 6: Absolute change in HDL (mmol/L
1.7. Analysis
1.7. Analysis
Comparison 1: IF vs Ad libitum (Short term), Outcome 7: Absolute change in TG (mmol/L)
1.8. Analysis
1.8. Analysis
Comparison 1: IF vs Ad libitum (Short term), Outcome 8: Absolute change in SBP (mmHg)
1.9. Analysis
1.9. Analysis
Comparison 1: IF vs Ad libitum (Short term), Outcome 9: Absolute change in DBP (mmHg)
1.10. Analysis
1.10. Analysis
Comparison 1: IF vs Ad libitum (Short term), Outcome 10: Absolute change in CRP (mg/L)
1.11. Analysis
1.11. Analysis
Comparison 1: IF vs Ad libitum (Short term), Outcome 11: Absolute change in Glucose (mmol/L)
2.1. Analysis
2.1. Analysis
Comparison 2: IF vs CER (Short term), Outcome 1: Absolute change in Body Weight (Total) (kg)
2.2. Analysis
2.2. Analysis
Comparison 2: IF vs CER (Short term), Outcome 2: Absolute change in Body Weight (Fasting subgroups) (kg)
2.3. Analysis
2.3. Analysis
Comparison 2: IF vs CER (Short term), Outcome 3: Absolute change in Body Weight (Female subgroup) (Kg)
2.4. Analysis
2.4. Analysis
Comparison 2: IF vs CER (Short term), Outcome 4: Absolute change in Body Weight (Overweight subgroups) (kg)
2.5. Analysis
2.5. Analysis
Comparison 2: IF vs CER (Short term), Outcome 5: Absolute change in Body Weight (Diabetes subgroups) (kg)
2.6. Analysis
2.6. Analysis
Comparison 2: IF vs CER (Short term), Outcome 6: Absolute change in BMI (kg/m2).
2.7. Analysis
2.7. Analysis
Comparison 2: IF vs CER (Short term), Outcome 7: Absolute change in waist circumference (cm)
2.8. Analysis
2.8. Analysis
Comparison 2: IF vs CER (Short term), Outcome 8: Absolute change in total cholesterol (mmol/l)
2.9. Analysis
2.9. Analysis
Comparison 2: IF vs CER (Short term), Outcome 9: Absolute change in LDL (mmol/L)
2.10. Analysis
2.10. Analysis
Comparison 2: IF vs CER (Short term), Outcome 10: Absolute change in HDL (mmol/L)
2.11. Analysis
2.11. Analysis
Comparison 2: IF vs CER (Short term), Outcome 11: Absolute change in TG (mmol/L)
2.12. Analysis
2.12. Analysis
Comparison 2: IF vs CER (Short term), Outcome 12: Absolute change in SBP (mmHg)
2.13. Analysis
2.13. Analysis
Comparison 2: IF vs CER (Short term), Outcome 13: Absolute change in DBP (mmHg)
2.14. Analysis
2.14. Analysis
Comparison 2: IF vs CER (Short term), Outcome 14: Absolute change in CRP (mg/L)
2.15. Analysis
2.15. Analysis
Comparison 2: IF vs CER (Short term), Outcome 15: Absolute change in Glucose (mmol/L
2.16. Analysis
2.16. Analysis
Comparison 2: IF vs CER (Short term), Outcome 16: Absolute change in HbA1c (mmol/L)
3.1. Analysis
3.1. Analysis
Comparison 3: IF vs CER (Medium term), Outcome 1: Absolute change in Body weight (kg)
3.2. Analysis
3.2. Analysis
Comparison 3: IF vs CER (Medium term), Outcome 2: Absolute change in BMI (kg/m2)
3.3. Analysis
3.3. Analysis
Comparison 3: IF vs CER (Medium term), Outcome 3: Absolute change in waist circumference (cm)
3.4. Analysis
3.4. Analysis
Comparison 3: IF vs CER (Medium term), Outcome 4: Absolute change in total cholesterol (mmol/L)
3.5. Analysis
3.5. Analysis
Comparison 3: IF vs CER (Medium term), Outcome 5: Absolute change in LDL (mmol/L)
3.6. Analysis
3.6. Analysis
Comparison 3: IF vs CER (Medium term), Outcome 6: Absolute change in HDL (mmol/L)
3.7. Analysis
3.7. Analysis
Comparison 3: IF vs CER (Medium term), Outcome 7: Absolute change in TG (mmol/L)
3.8. Analysis
3.8. Analysis
Comparison 3: IF vs CER (Medium term), Outcome 8: Absolute change in SBP (mmHg)
3.9. Analysis
3.9. Analysis
Comparison 3: IF vs CER (Medium term), Outcome 9: Absolute change in DBP (mmHg)
3.10. Analysis
3.10. Analysis
Comparison 3: IF vs CER (Medium term), Outcome 10: Absolute change in CRP (mg/L)
3.11. Analysis
3.11. Analysis
Comparison 3: IF vs CER (Medium term), Outcome 11: Absolute change in glucose (mmol/L)
4.1. Analysis
4.1. Analysis
Comparison 4: Sensitivity analysis; published data: IF vs Ad libitum (Short term), Outcome 1: Absolute change in body weight (kg)
4.2. Analysis
4.2. Analysis
Comparison 4: Sensitivity analysis; published data: IF vs Ad libitum (Short term), Outcome 2: Absolute change in BMI (kg/m2)
4.3. Analysis
4.3. Analysis
Comparison 4: Sensitivity analysis; published data: IF vs Ad libitum (Short term), Outcome 3: Absolute change in waist circumference (cm)
4.4. Analysis
4.4. Analysis
Comparison 4: Sensitivity analysis; published data: IF vs Ad libitum (Short term), Outcome 4: Absolute change in total cholesterol levels (TC) (mmol/L)
4.5. Analysis
4.5. Analysis
Comparison 4: Sensitivity analysis; published data: IF vs Ad libitum (Short term), Outcome 5: Absolute change in LDL (mmol/L)
4.6. Analysis
4.6. Analysis
Comparison 4: Sensitivity analysis; published data: IF vs Ad libitum (Short term), Outcome 6: Absolute change in HDL (mmol/L)
4.7. Analysis
4.7. Analysis
Comparison 4: Sensitivity analysis; published data: IF vs Ad libitum (Short term), Outcome 7: Absolute change in TG (mmol/L)
4.8. Analysis
4.8. Analysis
Comparison 4: Sensitivity analysis; published data: IF vs Ad libitum (Short term), Outcome 8: Absolute change in SBP (mmHg)
4.9. Analysis
4.9. Analysis
Comparison 4: Sensitivity analysis; published data: IF vs Ad libitum (Short term), Outcome 9: Absolute change in DBP (mmHg)
4.10. Analysis
4.10. Analysis
Comparison 4: Sensitivity analysis; published data: IF vs Ad libitum (Short term), Outcome 10: Absolute change in CRP (mg/L)
4.11. Analysis
4.11. Analysis
Comparison 4: Sensitivity analysis; published data: IF vs Ad libitum (Short term), Outcome 11: Absolute change in Glucose (mmol/L)
5.1. Analysis
5.1. Analysis
Comparison 5: Sensitivity analysis; published data: IF vs CER (Short term), Outcome 1: kbsolute change in Body Weight (Total) (kg)
5.2. Analysis
5.2. Analysis
Comparison 5: Sensitivity analysis; published data: IF vs CER (Short term), Outcome 2: Absolute change in Body Weight (Fasting subgroups) (kg)
5.3. Analysis
5.3. Analysis
Comparison 5: Sensitivity analysis; published data: IF vs CER (Short term), Outcome 3: Absolute change in Body Weight (Female subgroups) (kg)
5.4. Analysis
5.4. Analysis
Comparison 5: Sensitivity analysis; published data: IF vs CER (Short term), Outcome 4: Absolute change in Body Weight (Overweight subgroups) (kg)
5.5. Analysis
5.5. Analysis
Comparison 5: Sensitivity analysis; published data: IF vs CER (Short term), Outcome 5: Absolute change in Body Weight (Diabetes subgroups) (Kg)
5.6. Analysis
5.6. Analysis
Comparison 5: Sensitivity analysis; published data: IF vs CER (Short term), Outcome 6: Absolute change in BMI (kg/m2)
5.7. Analysis
5.7. Analysis
Comparison 5: Sensitivity analysis; published data: IF vs CER (Short term), Outcome 7: Absolute change in waist circumference (cm)
5.8. Analysis
5.8. Analysis
Comparison 5: Sensitivity analysis; published data: IF vs CER (Short term), Outcome 8: Absolute change in total cholesterol (mmol/L)
5.9. Analysis
5.9. Analysis
Comparison 5: Sensitivity analysis; published data: IF vs CER (Short term), Outcome 9: Absolute change in LDL (mmol/L)
5.10. Analysis
5.10. Analysis
Comparison 5: Sensitivity analysis; published data: IF vs CER (Short term), Outcome 10: Absolute change in HDL (mmol/L)
5.11. Analysis
5.11. Analysis
Comparison 5: Sensitivity analysis; published data: IF vs CER (Short term), Outcome 11: Absolute change in TG (mmol/L)
5.12. Analysis
5.12. Analysis
Comparison 5: Sensitivity analysis; published data: IF vs CER (Short term), Outcome 12: Absolute change in SBP (mmHg)
5.13. Analysis
5.13. Analysis
Comparison 5: Sensitivity analysis; published data: IF vs CER (Short term), Outcome 13: Absolute change in DBP (mmHg)
5.14. Analysis
5.14. Analysis
Comparison 5: Sensitivity analysis; published data: IF vs CER (Short term), Outcome 14: Absolute change in CRP (mg/L)
5.15. Analysis
5.15. Analysis
Comparison 5: Sensitivity analysis; published data: IF vs CER (Short term), Outcome 15: Absolute change in Glucose (mmol/L)
5.16. Analysis
5.16. Analysis
Comparison 5: Sensitivity analysis; published data: IF vs CER (Short term), Outcome 16: Absolute change in HbA1c (mmol/L)
6.1. Analysis
6.1. Analysis
Comparison 6: Sensitivity analysis: published data: IF vs CER (Medium term), Outcome 1: Absolute change in Body weight (kg)
6.2. Analysis
6.2. Analysis
Comparison 6: Sensitivity analysis: published data: IF vs CER (Medium term), Outcome 2: Absolute change in BMI (kg/m2)
6.3. Analysis
6.3. Analysis
Comparison 6: Sensitivity analysis: published data: IF vs CER (Medium term), Outcome 3: Absolute change in waist circumference (cm)
6.4. Analysis
6.4. Analysis
Comparison 6: Sensitivity analysis: published data: IF vs CER (Medium term), Outcome 4: Absolute change in total cholesterol (mmol/L)
6.5. Analysis
6.5. Analysis
Comparison 6: Sensitivity analysis: published data: IF vs CER (Medium term), Outcome 5: Absolute change in LDL (mmol/L)
6.6. Analysis
6.6. Analysis
Comparison 6: Sensitivity analysis: published data: IF vs CER (Medium term), Outcome 6: Absolute change in HDL (mmol/L)
6.7. Analysis
6.7. Analysis
Comparison 6: Sensitivity analysis: published data: IF vs CER (Medium term), Outcome 7: Absolute change in TG (mmol/L)
6.8. Analysis
6.8. Analysis
Comparison 6: Sensitivity analysis: published data: IF vs CER (Medium term), Outcome 8: Absolute change in SBP (mmHg)
6.9. Analysis
6.9. Analysis
Comparison 6: Sensitivity analysis: published data: IF vs CER (Medium term), Outcome 9: Absolute change in DBP (mmHg)
6.10. Analysis
6.10. Analysis
Comparison 6: Sensitivity analysis: published data: IF vs CER (Medium term), Outcome 10: Absolute change in glucose (mmol/L)

Source: PubMed

3
購読する